AI in Action E413: Rachel Liberatore, President & Chief Scientific Officer at RenBio
AI in Action, Podcast | January 20 2023 | JP Valentine
Welcome to episode 413 of the AI in Action podcast, the show where we break down the hype and explore the impact that Data Science, Machine Learning and Artificial Intelligence are making on our everyday lives.
Powered by Alldus International, our goal is to share with you the insights of technologists and data science enthusiasts to showcase the excellent work that is being done within AI in North America and Europe.
Today’s guest is Rachel Liberatore, President & Chief Scientific Officer at RenBio in New York. RenBio was founded in 1996 on the principle that the remarkable medical benefits of antibody therapeutics should be available to everyone. RenBio’s goal is to deliver antiviral antibodies to prevent the spread of infectious diseases, and improve the dosing regimen and effectiveness of therapeutic proteins.
Using RenBio’s Make Your Own (MYO) Technology, therapeutic-encoding “bioblueprints” are delivered via modified intramuscular injection, which are then decoded by the muscle cells to produce disease-fighting therapeutics in the patient’s own body. Their vision is to modernize and transform the antibody and therapeutic protein fields to significantly reduce the impact of diseases worldwide.
In the episode, Rachel will discuss:
The work Renbio are doing in the BioTech space
The role of data and new technology at RenBio
An insight into the team behind the scences
How the device works and insights they can gain
Their work with DARPA’s Pandemic Prevention Platform
Upcoming projects and What’s next for RenBio
To find out more about all the great work happening at RenBio, check out the website www.renbio.com or follow them on LinkedIn or Twitter @RenBioNYC. You can also connect with Rachel directly on LinkedIn or follow her on Twitter @rliberatore.
What did you think of Rachel’s podcast? Where do you see the future of AI and Data in the Biotech industry heading over the next few years? We would love to hear your thoughts on this episode, so please leave a comment below.
If you’re interested in exploring our latest Data Science &ML jobs, check out our live vacancies or upload your resume today to keep up to date with all the latest opportunities.
Subscribe to The Alldus Podcast:
Welcome to episode 413 of the AI in Action podcast, the show where we break down the hype and explore the impact that Data Science, Machine Learning and Artificial Intelligence are making on our everyday lives.
Powered by Alldus International, our goal is to share with you the insights of technologists and data science enthusiasts to showcase the excellent work that is being done within AI in North America and Europe.
Today’s guest is Rachel Liberatore, President & Chief Scientific Officer at RenBio in New York. RenBio was founded in 1996 on the principle that the remarkable medical benefits of antibody therapeutics should be available to everyone. RenBio’s goal is to deliver antiviral antibodies to prevent the spread of infectious diseases, and improve the dosing regimen and effectiveness of therapeutic proteins.
Using RenBio’s Make Your Own (MYO) Technology, therapeutic-encoding “bioblueprints” are delivered via modified intramuscular injection, which are then decoded by the muscle cells to produce disease-fighting therapeutics in the patient’s own body. Their vision is to modernize and transform the antibody and therapeutic protein fields to significantly reduce the impact of diseases worldwide.
In the episode, Rachel will discuss:
The work Renbio are doing in the BioTech space
The role of data and new technology at RenBio
An insight into the team behind the scences
How the device works and insights they can gain
Their work with DARPA’s Pandemic Prevention Platform
Upcoming projects and What’s next for RenBio
To find out more about all the great work happening at RenBio, check out the website www.renbio.com or follow them on LinkedIn or Twitter @RenBioNYC. You can also connect with Rachel directly on LinkedIn or follow her on Twitter @rliberatore.
What did you think of Rachel’s podcast? Where do you see the future of AI and Data in the Biotech industry heading over the next few years? We would love to hear your thoughts on this episode, so please leave a comment below.
If you’re interested in exploring our latest Data Science &ML jobs, check out our live vacancies or upload your resume today to keep up to date with all the latest opportunities.
Subscribe to The Alldus Podcast:
share
related podcasts
AI in Action E559: ‘Uncovering AI’s Potential in National Security’ with Improvix Technologies’ Jack Loss
Welcome to episode 559 of the AI in Action podcast, the show where we break down the hype and explore the impact that Data Science, Machine Learning and Artificial Intelligence are making on our everyday lives. Powered by Alldus International, our goal is to share with you the insights of technologists and data science enthusiasts…
AI in Action E558: ‘Building AI-Powered Solutions for the Legal industry’ with ALM’s Jimi Li
Welcome to episode 558 of the AI in Action podcast, the show where we break down the hype and explore the impact that Data Science, Machine Learning and Artificial Intelligence are making on our everyday lives. Powered by Alldus International, our goal is to share with you the insights of technologists and data science enthusiasts…
AI in Action E557: ‘AI Governance and Cyber Threats’ with KontentAI’s Matej Zachar
Welcome to episode 557 of the AI in Action podcast, the show where we break down the hype and explore the impact that Data Science, Machine Learning and Artificial Intelligence are making on our everyday lives. Powered by Alldus International, our goal is to share with you the insights of technologists and data science enthusiasts…